8-K: Fortrea Reports Mixed 2025 Results, Issues 2026 Guidance

Fortrea Holdings Inc. reported full-year 2025 revenues of $2.72 billion and a significant GAAP net loss, while providing 2026 revenue and adjusted EBITDA guidance.

Summary

• Full-year 2025 revenue reached $2,723.4 million, an increase from $2,696.4 million in 2024.
• A GAAP net loss of $(986.2) million, or $(10.81) per diluted share, was reported for full-year 2025, primarily due to a non-cash goodwill impairment charge of $797.9 million recognized in the first half of the year.
• Adjusted EBITDA for full-year 2025 was $189.9 million, a decrease from $202.5 million in 2024.
• Adjusted net income for full-year 2025 increased to $40.4 million, or $0.43 per diluted share, compared to $30.1 million, or $0.33 per diluted share, in 2024.
• Fourth-quarter 2025 revenue was $660.5 million, down from $697.0 million in the fourth quarter of 2024.
• The book-to-bill ratio for the fourth quarter of 2025 was 1.14x, resulting in a 1.02x book-to-bill for the trailing 12 months.
• Backlog as of December 31, 2025, stood at $7,728.0 million.
• Cash and cash equivalents were $174.6 million, and gross debt was $1,066.3 million as of December 31, 2025.
• Operating cash flow for full-year 2025 was $113.5 million, with free cash flow at $88.3 million.
• For full-year 2026, the company targets revenues in the range of $2,550 million to $2,650 million and adjusted EBITDA in the range of $190 million to $220 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with significant GAAP losses driven by impairment, offset by some operational improvements and positive adjusted net income growth. The lower 2026 revenue guidance is a concern, despite management's optimistic tone.

Positives

• Full-year 2025 revenue increased to $2,723.4 million from $2,696.4 million in 2024.
• Full-year 2025 adjusted net income increased to $40.4 million ($0.43 per diluted share) from $30.1 million ($0.33 per diluted share) in 2024.
• Fourth-quarter 2025 book-to-bill ratio was strong at 1.14x, contributing to a positive trailing 12-month book-to-bill of 1.02x.
• Backlog as of December 31, 2025, was substantial at $7,728.0 million, providing future revenue visibility.
• Operating cash flow for full-year 2025 was $113.5 million, and free cash flow was $88.3 million, indicating healthy cash generation.
• Cash and cash equivalents increased to $174.6 million as of December 31, 2025, from $118.5 million in 2024.
• Management noted positive feedback from large pharma and biotech clients and strengthened the balance sheet through disciplined capital allocation and continued debt paydown.

Negatives

• Full-year 2025 GAAP net loss was significant at $(986.2) million, or $(10.81) per diluted share, primarily due to a non-cash goodwill impairment charge of $797.9 million.
• Full-year 2025 Adjusted EBITDA decreased to $189.9 million from $202.5 million in 2024.
• Fourth-quarter 2025 revenue decreased to $660.5 million from $697.0 million in Q4 2024.
• Fourth-quarter 2025 Adjusted EBITDA decreased to $54.0 million from $56.0 million in Q4 2024.
• The 2026 revenue guidance range of $2,550 million to $2,650 million is lower than the 2025 actual revenue of $2,723.4 million, indicating an expected revenue decline.
• Gross debt remains high at $1,066.3 million as of December 31, 2025.

Risks

• Dependence on third parties generally to provide services critical to the business.
• Ability to successfully implement business strategies and execute the long-term value creation strategy.
• Risks and expenses associated with international operations, tariff policies, trade sanctions and other trade restrictions, and currency fluctuations.
• Customer or therapeutic area concentrations.
• Adoption and use of technology within the business and the risks that the company may not be able to capture the anticipated benefits of such technology or that such technology may have negative effects.
• The outcome and impact of pending or future litigation.
• Any further deterioration in the macroeconomic environment, particularly within the pharmaceutical and biotechnology industry, or further changes in government regulations and funding, which could lead to defaults or cancellations by customers.
• The risk that backlog and net new business may not be indicative of future revenues and that the company might not realize all of the anticipated future revenue reflected in backlog.
• Ability to generate sufficient net new business awards, or if net new business awards are delayed, terminated, reduced in scope, or fail to go to contract.
• Underpricing contracts, overrunning cost estimates, or failing to receive approval for, or experiencing delays in documentation of change orders.

Future Outlook

For the full year 2026, Fortrea targets revenues in the range of $2,550 million to $2,650 million and adjusted EBITDA in the range of $190 million to $220 million. This guidance assumes foreign currency exchange rates as of December 31, 2025, remain in effect for the forecast period.

Management Comments

• "We finished 2025 with solid results for the fourth quarter, as the Fortrea team's shared commitment to commercial, operational and financial excellence becomes embedded in our way of working." Anshul Thakral, CEO.
• "After a challenging first half of the year, we delivered a second half of strong book-to-bills." Anshul Thakral, CEO.
• "I'm proud not only of what we achieved but also how we achieved it. Our large pharma and biotech clients are giving our project teams very positive feedback across the board, as we work to meet and exceed their expectations every day." Anshul Thakral, CEO.
• "At the same time, we strengthened our balance sheet through disciplined capital allocation and continued debt paydown." Anshul Thakral, CEO.
• "We have continued to deliver and innovate, beginning the new year on strong footing for our journey back to growth and margin expansion." Anshul Thakral, CEO.

Industry Context

StockSavvy.ai notes that Fortrea operates in the competitive global contract research organization (CRO) industry, which is influenced by biopharmaceutical R&D spending and macroeconomic conditions. The company's focus on operational excellence and client feedback is crucial in a sector where service quality and efficiency are key differentiators. The reported strong book-to-bills in the second half of 2025 suggest a potential recovery in client engagement following earlier challenges, aligning with broader industry trends of fluctuating R&D investment cycles.

Legal Proceedings

• The company faces risks related to the outcome and impact of pending or future litigation.
• Adjustments for non-GAAP measures included settlements related to litigation initiated prior to the spinoff of the company as a standalone entity.

Stakeholder Impact

• Shareholders: Significant GAAP net loss due to goodwill impairment could negatively impact investor confidence and share price. Adjusted net income growth and positive free cash flow offer some reassurance. Lower 2026 revenue guidance may temper growth expectations.
• Employees: Restructuring charges mentioned in non-GAAP adjustments (though not new for 2025) indicate ongoing efforts to align resources, which could impact employee morale or job security.
• Customers: Positive feedback from large pharma and biotech clients suggests strong service delivery, which is crucial for retaining and attracting business.
• Creditors: Continued debt paydown and disciplined capital allocation strengthen the balance sheet, which is positive for creditors. Gross debt remains substantial.

Next Steps

• Fortrea will host an earnings call at 8:00 am ET on February 26, 2026, to discuss financial results and 2026 guidance.
• The company aims for a journey back to growth and margin expansion.

Key Dates

Recommendation

While the significant GAAP net loss due to goodwill impairment is a major negative, it is a non-cash charge. The company showed growth in adjusted net income, positive free cash flow, and strong book-to-bill in the latter half of 2025, indicating operational improvements. However, the 2026 revenue guidance projects a decline, suggesting ongoing challenges. The stock is likely to experience volatility, but the underlying operational improvements and backlog provide a basis for a 'hold' rather than a 'sell,' awaiting clearer signs of sustained revenue growth.

Keywords

Fortrea, FTRE, financial results, 2025 earnings, 2026 guidance, revenue, adjusted EBITDA, GAAP net loss, book-to-bill, backlog, CRO, contract research organization, clinical development, life sciences